Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

NOXCOVID Trial Advances to Final Stage (ASX:NOX)

Positive review of hospitalized COVID-19 patients triggers approval to move from Part 1 to Part 2 of the trial Top dose of 1800 mg Veyonda daily to be used in final patient cohort Tests on blood ...read more

Immutep expands Part B of TACTI-002 collaboration trial (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has decided to expand Part B of...read more

Acorn Capital Investment Fund - Dividend/Distribution

To view the Notification of dividend / distribution, download the attached PDF.

Acorn Capital Investment Fund - Details of Company Address

In accordance with ASX Listing Rule 3.14, Acorn Capital Investment Fund Limited (ASX: ACQ) wishes to advise that as of immediate effect its registered office and principle place of business will cha...read more

Acorn Capital Investment Fund - Half Year Accounts

To view the Appendix 4D - Half Year Report for the half year ended 31 December 2020, download the attached PDF.

Xplore Wealth - Appendix 4D and Half Year Financial Report (ASX:XPL)

Xplore Wealth Limited (ASX: XPL) (the Company) releases its Appendix 4D (Half Year Report) and Interim Report for the half year ended 31 December 2020, as approved by the Board. For more informat...read more

Chimeric Therapeutics - Half Yearly Report and Accounts (ASX:CHM)

To view the report, download the attached PDF.

BrainChip Holdings - Annual Report FY20 (ASX:BRN)

To view the annual report, download the attached PDF.

BrainChip Holdings - Appendix 4G and Corporate Governance Statement (ASX:BRN)

To view the appendix, download the attached PDF.

BrainChip Holdings - Appendix 4E (ASX:BRN)

To view the preliminary final report, download the attached PDF.

SUDA Pharmaceuticals - Anagrelide Project Update (ASX:SUD)

SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, advises that SUDA has contracted the services of MedPharm, who will perform formulation development work to assist in stab...read more

SUDA Pharmaceuticals - Appendix 4D & Interim Financial Half Year Report FY2021 (ASX:SUD)

To view the FY21 half year results, download the attached PDF.

Lepidico - Financial Report for the half year ended 31 December 2020 (ASX:LPD)

Lepidico Ltd (ASX:LPD) (“Lepidico” or “Company”) is pleased to announce the release of its reviewed consolidated financial statements for the half year ended 31 December 2020...read more

MMJ Group Holdings - Harvest One Investment Update (ASX:MMJ)

MMJ Group Holdings Limited (ASX: MMJ/OTC Code MMJJF) ("MMJ") is an Australian-listed company whose core business is holding minority investments along the cannabis value-chain in Australia...read more

Cyclopharm Results Summary (ASX:CYC)

Cyclopharm Limited (ASX: CYC) is pleased to provide the following update on its business and financial performance for FY2020, including progress towards gaining United States Food and Drug Administ...read more

Viewing: 1 - 15 of 200 Previous | Next